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AbstrACt
Introduction There is consistent evidence that 
people with cerebral palsy (CP) do not engage in the 
recommended physical activity guidelines for the general 
population from a young age. Participation in moderate- 
to- vigorous physical activity is particularly reduced in 
people with CP who have a moderate- to- severe disability. 
RaceRunning is a growing disability sport that provides an 
opportunity for people with moderate- to- severe disability 
to participate in physical activity in the community. It 
allows those who are unable to walk independently to 
propel themselves using a RaceRunning bike, which has 
a breastplate for support but no pedals. The aim of this 
study is to examine the feasibility and acceptability of 
RaceRunning for young people with moderate- to- severe 
CP and the feasibility of conducting a definitive study of 
the effect of RaceRunning on cardiometabolic disease risk 
factors and functional mobility.
Methods and analysis Twenty- five young people 
(age 5–21 years) with CP or acquired brain injury 
affecting coordination will be included in this single- 
arm intervention study. Participants will take part in one 
RaceRunning session each week for 24 weeks. Outcomes 
assessed at baseline, 12 and 24 weeks include body 
mass index, waist circumference, blood pressure, muscle 
strength, cardiorespiratory fitness, physical activity 
and sedentary behaviour, functional mobility, activity 
competence and psychosocial impact. Adverse events 
will be systematically recorded throughout the 24 weeks. 
Focus groups will be conducted with participants and/or 
parents to explore their views and experiences of taking 
part in RaceRunning.
Ethics and dissemination Approval has been 
granted by Queen Margaret University Research Ethics 
Committee (REC) and the South East of Scotland REC. 
Results will be disseminated through peer- reviewed 
journals and distributed to people with CP and their 
families through RaceRunning and Athletic Clubs, 
National Health Service trusts and organisations for 
people with disabilities.
trial registration number NCT04034342; pre- results.
IntroduCtIon
Cerebral palsy (CP) is an umbrella term for 
disorders affecting the development of move-
ment and posture, which cause limitations 
in activities of daily living. Although CP is 
considered a non- progressive neurological 
condition, it often results in secondary condi-
tions such as contractures, bone deformi-
ties, muscle weakness and fatigue leading to 
further decreased mobility.1 2 Mobility often 
worsens with age and can lead to diminished 
independence.3 These secondary condi-
tions may lead to a negative cycle of phys-
ical inactivity and further deconditioning.4 5 
Indeed, there is ample evidence that, from 
a young age, people with CP do not engage 
in the recommended activity levels for the 
general population and children with CP of 
60 min moderate- to- vigorous physical activity 
(MVPA) per day.4 Participation in MPVA is 
particularly reduced in people with CP who 
have a moderate- to- severe disability. Claridge 
et al reported that children in Gross Motor 
Function Classification System (GMFCS) 
level I participated in 40 min of MVPA per day 
and this decreased with increasing GMFCS 
strengths and limitations of this study
 ► This multicentre study will examine the feasibility 
and acceptability of RaceRunning for young people 
with moderate- to- severe cerebral palsy as well as 
the feasibility of conducting a definitive study of the 
effect of RaceRunning.
 ► People with a range of severities of motor impair-
ment will be included.
 ► A range of outcomes relating to cardiometabolic risk 
will be assessed.
 ► There will be no control group included in the study.
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level to 5.5, 0.71 and 0.64 min for children in GMFCS 
levels III, IV and V, respectively.6 Reduced participation in 
MVPA is a modifiable risk factor for non- communicable 
diseases (WHO) and likely contributes to the increased 
risk of cardiovascular disease observed in people with 
CP.4 In both adults and children with CP, participation 
in MVPA is associated with reductions in risk factors for 
cardiometabolic diseases such as elevated blood pressure 
and abdominal obesity.7 8 Further, breaks from sedentary 
behaviour are associated with reductions in risk factors, 
independent of total time in MVPA in people without 
disability,9 which may be feasible for children with CP to 
achieve.
In recent years, efforts have been directed towards 
examining the effectiveness of exercise and physical 
activity interventions for independently ambulant people 
with CP.10 11 However, there is a lack of research examining 
the effectiveness of exercise interventions for people with 
CP with moderate- to- severe disability.10 Limited access to 
adapted physical activities may contribute to the lack of 
participation in MVPA among people with moderate- to- 
severe disability. RaceRunning ( www. racerunning. org) 
is a growing disability sport that provides an opportunity 
for people with moderate- to- severe disability to partici-
pate in physical activity in the community. It allows those 
who are unable to walk independently to propel them-
selves using a RaceRunning bike, which has a breastplate 
for support but no pedals. Participants sit on the saddle 
and use their legs to propel themselves forward. It is esti-
mated that worldwide approximately 2000 running bikes 
are used for participation in sport (ie, training sessions 
and competitions), physical education and therapy. Pilot 
studies suggest that people with CP can achieve MVPA 
while taking part in RaceRunning.12 13 Non- controlled 
small studies also indicate that RaceRunning has positive 
effects on aerobic capacity, bone health and muscle thick-
ness.14 15 However, the quality of the evidence from these 
studies is low and no study has assessed the long- term 
sustainability of RaceRunning or its impact on cardiomet-
abolic risk factors and functional mobility in people with 
CP. Before conducting a definitive cohort study on the 
effect of RaceRunning, the feasibility of conducting such 
a study needs to be determined.
The aim of this study is to examine the feasibility and 
acceptability of RaceRunning for young people with 
moderate- to- severe CP and the feasibility of conducting 
a definitive study of the effect of RaceRunning on 




This is a multicentre single- arm intervention study. 
Assessments will be conducted at baseline, 12 and 24 
weeks. Participants will be recruited from RaceRunning 
clubs, athletics clubs and National Health Service (NHS) 
trusts in Scotland and Gloucestershire. The study will also 
be advertised through social media and via organisations 
for people with disabilities. Potentially eligible partic-
ipants will be provided with an invitation letter and an 
age- appropriate Participant Information Sheet. Parents 
of potential participants aged <16 years will be provided 
with a parent information sheet.
Participants
Twenty- five young people aged 5–21 years with CP or 
acquired brain injury affecting coordination will be 
included in the study. Participants are eligible to be 
included in the trial if they use wheeled mobility indoors 
and/or outdoors, but they may use an assistive mobility 
device indoors instead of a wheelchair. For children with 
CP, this encompasses children in GMFCS levels III, IV 
or V. Additional inclusion criteria are: having less than 
15 hours of RaceRunning experience, ability to inde-
pendently propel the bike for at least 30 m and ability 
to comprehend and follow instructions relating to 
participation in RaceRunning training. Participants will 
be excluded if they had lower limb surgery or selective 
dorsal rhizotomy less than 6 months prior to the start of 
the study or have a severe visual impairment affecting the 
ability to safely take part in RaceRunning training. Chil-
dren and young people who have been receiving regular 
Botox injections and baclofen treatment for more than 
6 months will be included in the study, but these will be 
recorded in the trial notes.
Intervention
Participants will take part in one RaceRunning session 
each week for 24 weeks. This hourly session will be led by 
an experienced RaceRunning coach, who has attended 
the RaceRunning coaching course (organised by Race-
Running Scotland or CP Sport England) and/or is a level 
1 or 2 UK athletics coach. The coach will be supported 
by a physiotherapist or other health professional and 
(student) volunteers.
Content of the sessions will be standardised for all 
training groups and will consist of warmup, coordi-
nation, endurance and sprint training drills, and a 
cool- down period. Coordination training will be approx-
imately 10 min in duration and consist of drills such as 
mouse steps (feet touching the ground as many times as 
possible), overexaggerated strides, one- foot pushes, high 
knees and two- foot pushes. Endurance training will be 
approximately 10–15 min duration and consist of steady 
running. Sprint training will consist of four to five short 
sprints over between 10 m and 60 m, depending on ability.
outcome measures
Demographic, CP- related characteristics and self- 
reported physical activity will be assessed at baseline. The 
Physical Activity Questionnaire for Children (PAQ- C) and 
Adolescents (PAQ- A) will be used to assess self- reported 
physical activity. Both questionnaires provide a summary 
of physical activity scores derived from nine items, each 
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scored on a 5- point scale. The PAQ- C and PAQ- A are valid 
and reliable in children.16–18
The following outcomes will be assessed at baseline, 12 
and 24 weeks. Questionnaires will be completed at Queen 
Margaret University or the University of Gloucestershire, 
or at the participant’s home if requested. Objective 
measures will be assessed at the location where RaceRun-
ning sessions are completed. Participants will be asked 
to refrain from strenuous or unusual exercise 24 hours 
before the assessment and to have a light meal at least 
2 hours before the assessment of objective measures. 
Assessors will follow a standardised protocol to complete 
all assessments.
Body mass index
Body mass will be measured to the nearest kilogram using 
flat medical scales (Seca). For those who are not able to 
stand independently, the weight will be recorded while 
sitting on a chair on the scales. For participants who are 
able to stand (with or without support), body height 
will be measured (to the nearest millimetre (mm)) in 
standing using a portable stadiometer. For those who 
are unable to stand unsupported, a height measurement 
will be taken supine, also using a portable stadiometer. 
In case of severe contractures in both legs, knee height 
will be measured and used to estimate the height using 
published, validated equations based on a population of 
children with CP.19 Body mass index will be calculated as 
mass divided by height squared (kg/m2).
Waist circumference
For waist circumference, midpoints between the lower rib 
margin and the iliac crest will be marked and the circum-
ference will be measured to the nearest mm by posi-
tioning the measuring tape over the mid- distance mark 
on both sides. This method has shown to have adequate 
reliability and measurement error in children.20
Thigh and calf circumference
For an estimation of the muscle bulk, a tape measure will 
be used to measure thigh and calf circumference to the 
nearest mm. For the calf, the location of the circumfer-
ence measurement will be in the most prominent point 
of the muscle belly. For the thigh, the measurement point 
will be at 50% on the line from the anterior superior iliac 
spine to the superior part of the patella. The average of 
three measurements will be used for the analysis.
Resting heart rate and blood pressure
Heart rate will be assessed using SunTech Tango M2 in 
DKA mode for the recording of resting ECG. Three chest 
ECG electrodes will be used to record resting ECG. If 
this is not feasible (eg, lack of cooperation of the young 
person), then resting heart rate will be recorded through 
a chest belt.
Blood pressure will be assessed using an automated 
blood pressure monitor with an appropriately sized cuff. 
The cuff, with an integrated microphone for the auto-
matic detection of the Korotkoff sound, will be placed 
on the left arm with the centre of the bladder over the 
brachial artery. The bladder will encircle at least 80% of 
the arm but not more than 100%. The participant will be 
asked to sit quietly for between 5 min and 10 min in an 
upright position with his/her back against the chair and 
the measurement arm supported at the level of the heart.
After sitting quietly for at least 5 min, resting blood 
pressure and heart rate will be recorded in triplicate, with 
a 1 min interval between measurements. The average of 
the three readings of systolic blood pressure (mm Hg), 
diastolic blood pressure (mm Hg) and heart rate (bpm) 
will be used in the analysis. Efforts will be made to assess 
blood pressure and heart rate at a similar time of day at all 
assessments. Assessment will take place in a private, quiet, 
well- ventilated room of adequate size.
Knee extensor muscle strength
Knee extensor strength will be assessed using digital 
myometry in sitting with the knee flexed in 90°. This test 
will be repeated two times with each leg. It is a reliable 
method of measuring strength in children with CP.21
Cardiorespiratory fitness
There are currently no validated measures of maximum 
aerobic capacity for people with moderate- to- severe CP 
who are non- ambulant and/or unable to propel a wheel-
chair. For this research, a RaceRunning specific field- 
based maximal incremental test for determining peak 
oxygen consumption (V̇O2peak) will be used. The test is 
based on existing field- based incremental protocols for 
young people with CP.22 Instead of 10 m shuttles, as in 
the original tests, cones will be placed around the track 
every 10 m, which will avoid the participants having to do 
a 180° turn. Participants will walk/run between each cone 
at a set incremental speed determined by a signal. Those 
participants who are able to complete 100 m in less than 
40 s will perform an adapted shuttle run test for GMFCS 
level I (Shuttle RaceRunning test I (SRRT- I)), others will 
perform the adapted shuttle run test for GMFCS level 
II (Shuttle RaceRunning test II (SRRT- II)). Both tests 
consist of 23 levels each lasting 1 min with an increase 
in the speed of 0.25 km/hour at each level. The starting 
speed of the SRRT- I is 5 km/h and the starting speed of 
the SRRT- II is 2 km/hour. The test will end on reaching 
volitional exhaustion. If participants do not complete 
one shuttle within the allocated time, then they will be 
encouraged to continue. The test will be terminated if 
the participants do not complete two consecutive shuttles 
within the allocated time.
Expired gas exchange data will be collected in real time 
throughout the test using a portable online gas analyser 
(Metamax 3B (CORTEX Biophysik GmbH, Germany)). 
Heart rate will be monitored throughout the test using a 
chest- based transmitter (H10, Polar) and recorded by the 
Metamax software at a sample rate of 60 Hz.
The test protocol described previously allows direct 
measurement of the following outcomes: V̇O2peak, ventila-
tory threshold, minute ventilation, breathing frequency, 
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submaximal and maximal heart rate, respiratory 
exchange ratio, ventilatory efficiency ratios and O2 pulse. 
V̇O2peak will be determined as the highest observed value 
of V̇O2 over a 10 s epoch during the last completed 20 s in 
the final stage of the test. In addition, we will assess work 
efficiency at different exercise intensities that will corre-
spond to a complete stage of the SRRT.
Physical activity and sedentary behaviour
Steps per day, time spent in an upright position per day, 
number of transfers per day and time spent in sitting 
and lying (ie, sedentary time) will be recorded using the 
activPAL3µ activity monitor. The activPAL3µ is a small, 
lightweight device that is worn on the anterior aspect of 
the person’s thigh. It incorporates accelerometry and 
inclinometry data to provide information on the volume 
of time people spend in sedentary, upright and ambula-
tory activities. The activPAL is a valid measure of activity 
in children with CP.23
Participants will be asked to wear the activPAL3µ on 
their least affected leg for 7 continuous days. They will be 
asked to remove the monitor only for bathing and swim-
ming. Participants will be provided with instructions on 
how to attach the monitor and a diary to log time spent 
sleeping and non- wear time. Participants will return the 
monitors at the training session after the assessment or 
via post in a stamped addressed envelope provided by the 
researcher.
Functional mobility
The Functional Mobility Scale (FMS) will be used to 
assess functional mobility. The FMS describes the level 
of a child’s functional mobility in everyday life over 5, 50 
and 500 m, representing the home, school and commu-
nity settings, respectively.24 For each distance, an ordinal 
rating from 1 (wheelchair) to 6 (confident walking on all 
surfaces) is assigned depending on the amount of assis-
tance required for the child’s mobility.
Activity competence
The Canadian Occupational Performance Measure 
(COPM) will be used to identify important physical activ-
ities for each participant and to record the change in 
participants’ perceived performance of this activity and 
the satisfaction with this performance over time.25 The 
COPM is reliable and valid for use in young people.26
At baseline, in a semistructured interview, the 
researcher will ask the participant (or where appropriate 
the parents/carer together with, the or on behalf of the 
participant) to identify up to five physical activity- related 
activities of daily living, which are important but prob-
lematic to the participant. The participant will then be 
asked to rate his/her current performance on each of 
these activities on a Visual Analogue Scale ranging from 
1 (cannot do at all) to 10 (no problem at all) at 12- week 
and 24- week assessments, the researcher will list the same 
five activities and the participant will be asked to repeat 
the rating of his/her performance and satisfaction on 
these activities. A change score of ≥2 is considered clini-
cally meaningful in the COPM manual,27 whereas a study 
with older adults reported an optimal cut- off value ranged 
from 0.9 and 1.9.28
Psychosocial impact
The Psychosocial Impact of Assistive Devices Scale will be 
used to record the impact of using a RaceRunner on a 
range of psychosocial outcomes such as happiness, self- 
esteem, independence and quality of life. It is a valid 
and reliable tool that consists of 26 items and can be 
completed by the parents/carer together with, the or on 
behalf of the participant.29
Adverse events
The safety of the intervention will be determined by 
recording the incidence of adverse events (AEs) including 
falls and injuries between baseline and 24 weeks. An AE 
will be defined as ‘any untoward medical occurrence 
affecting a participant that does not necessarily have a 
causal relationship with the intervention’.30 At 12 and 
24 weeks, researchers will systematically enquire about 
changes in the participant’s health or any AEs since the 
last assessment. Standardised questioning will be used 
to probe the participant regarding specific types of AEs, 
for example, falls, injuries, increase in muscle pain or 
spasticity. Participants will also be asked to record any 
AEs experienced during training in their RaceRunning 
diaries. Trainers will also be asked to contact the research 
team if the participant experiences an AE while partici-
pating in the intervention. The following are expected 
non- serious AEs in response to the intervention: delayed 
onset muscle soreness, mild fatigue, saddle discomfort, 
shoe scuffing and foot discomfort.
A serious AE will be defined as an untoward medical 
occurrence/effect that results in death, is life- threatening, 
requires hospitalisation or prolongation of existing hospi-
talisation, or results in persistent or significant disability 
or incapacity.
Economic evaluation
This study will assess the feasibility of conducting an 
economic evaluation alongside a definitive cohort study 
of the effects of RaceRunning to reduce cardiometa-
bolic disease risk and improve functional mobility. For 
this study, we will assess the feasibility of collecting data 
on health service use and health- related quality of life. 
Health service use will be assessed using a modified 
version of the Client Service Receipt Inventory (CSRI). 
The CSRI collects retrospective information on service 
utilisation, service- related issues and income.31 Health- 
related quality of life will be assessed using the EuroQol-5 
dimension (Youth) (EQ- 5D- Y).32
Process evaluation
Fidelity
Fidelity to the intervention will be assessed by recording 
the overall volume of aerobic exercise achieved during 
RaceRunning, according to the Frequency, Intensity, 
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Time, Type (FITT) principle. Attendance, training dura-
tion and content for every session will be recorded by 
the coach. The intensity of the training sessions will be 
assessed for each participant by monitoring heart rate 
during three training sessions at week 1, 12 and 20 of the 
intervention.
Between week 3 and 8, 9 and 16, and 17 and 24, respec-
tively, participants will be filmed during a RaceRunning 
session using a standard video camera for analysis of their 
running characteristics such as the propulsion technique 
(eg, bilateral, unilateral, in- phase), presence of foot drag 
and the presence of involuntary head or upper limb move-
ment. This analysis of movement technique will enhance 
our understanding of the factors influencing maximum 
aerobic capacity and work efficiency.
Qualitative data collection
Focus groups will be conducted from a constructivist 
phenomenological perspective, aiming to explore a 
socially constructed phenomenon from the perspectives 
of participants. This balances different ways of looking 
at knowledge and knowing, and we will prioritise the 
constructivist perspective in analysis whenever possible.33 
Focus groups will be conducted with participants and/or 
their parents where appropriate to explore the views and 
experiences on taking part in RaceRunning.
Topic guides for the focus groups will be developed and 
piloted by the research team based on the study aims and 
available literature. An experienced qualitative researcher 
from Queen Margaret University will facilitate the focus 
groups, flexibly based around the topic guide. The focus 
groups will last around 60 min and will be recorded using 
digital audio recorders. There will also be an observer 
present who will take field notes (eg, body language) 
during the focus group. The digital audio- recordings 
of the focus groups will be transcribed verbatim by the 
researcher and supplemented by observer notes.
Patient and public involvement
A person with CP was involved in the design of the study 
and will be involved in the conduct and reporting of the 
study.
data analysis
As this is a feasibility study, no formal statistical analysis of 
the effectiveness of the intervention will be undertaken. 
The analysis will be conducted in order to determine the 
feasibility and acceptability of the intervention, and the 
feasibility of conducting a definitive study.
Descriptive statistics (eg, mean, SD, range, median, 
IQR and percentages) will be used to report recruitment, 
retention, attendance at RaceRunning sessions, outcome 
measure completion, and outcomes and AEs at baseline, 
12 and 24 weeks, respectively. Generalised estimating 
equations will be used to explore changes in outcomes 
over 24 weeks. Analyses will be conducted using Stata 
(Statcorp) and SPSS 27 (IBM Corp).
Qualitative data analysis
The analysis will be carried out separately for data 
collected from children and data collected from parents. 
Transcripts will be read for the initial understanding and 
a participant summary will be prepared for each focus 
group. Feedback will be sought from the participants 
on the summary, which will be added to the transcripts. 
For the next stage of analysis, the researcher will familia-
rise with the data while noting down initial observations, 
which will be followed by the coding of the whole data set. 
With the help of these codes, the text with similar mean-
ings will be thereby categorised to themes with assigned 
labels and definitions. A second researcher will carry out 
a secondary analysis of a selected sample to check the 
coding and interpretation and for confirming themes. 
Any lack of agreement between the researchers on inter-
pretation or themes will be resolved through discus-
sion. Any modification will be applied to the relevant 
sample. Relationships between themes may be explored 
if evidence of links exists and/or themes may be grouped 
into further categories. Qualitative software NVIVO will 
be used for interview analysis.
sample size
This is a feasibility study and thus no sample size calcu-
lation has been performed. Twenty- five people will be 
recruited to the study.
EthICs And dIssEMInAtIon
The trial will be conducted in full conformance with the 
principles of the Declaration of Helsinki and to MRC 
Good Clinical Practice (GCP) guidelines. All researchers 
working on the trial will receive training in GCP- ICH 
guidelines. It will also comply with all applicable UK legis-
lation and Queen Margaret University and the University 
of Gloucestershire Research integrity guidance.
The study has ethical approval from the South East Scot-
land Research Ethics Committee and Queen Margaret 
University Research Ethics Committee (reference 19/
SS/0035). Written informed consent will be obtained 
from participants aged 16 years and older. For those 
aged 16–17 years, written informed consent will also be 
obtained from a parent/guardian. Written informed 
assent will be obtained from participants younger than 
16 years of age and written informed consent will be 
obtained from his/her parent or guardian.
The findings for this study will be distributed through 
peer- reviewed journals, RaceRunning and Athletic Clubs, 
NHS trusts, organisations for people with disabilities, for 
example, CP Sport, and at national and international 
conferences.
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